HMPL-A83 / Hutchmed - LARVOL DELTA

A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors (ESMO Asia 2025) - P1 | "A83 was well-tolerated up to 30 mpk Q2W and 45 mpk Q3W with no hemolytic anemia observed. A83 did not require a lower 'priming' dose to prevent anemia. Combination with immunotherapy may warrant further evaluation."

Clinical • First-in-human • Metastases • P1 data • Oncology • Pancreatic Cancer • Solid Tumor • SIRPA

Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors…will be presented at the ESMO Asia Congress 2025 (GlobeNewswire)

First-in-human • P1 data • Solid Tumor

A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Hutchmed | Recruiting ➔ Completed | N=99 ➔ 40 | Trial completion date: Sep 2025 ➔ Apr 2025

Enrollment change • Trial completion • Trial completion date • Acute Myelogenous Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology

A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm (clinicaltrials.gov) - P1 | N=99 | Recruiting | Sponsor: Hutchmed | Trial primary completion date: Feb 2024 ➔ Jun 2025

Metastases • Trial primary completion date • Acute Myelogenous Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology

A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm (clinicaltrials.gov) - P1 | N=99 | Recruiting | Sponsor: Hutchmed | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China (GlobeNewswire) - "HUTCHMED...announces that it has initiated a Phase I trial in China of HMPL-A83, an investigational novel IgG4-type humanized anti-CD47 monoclonal antibody. The first patient received their first dose on July 15, 2022. The Phase I trial is a multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-A83 in patients with advanced malignant neoplasms."

Trial status • Oncology

A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm (clinicaltrials.gov) - P1 | N=99 | Not yet recruiting | Sponsor: Hutchison Medipharma Limited

New P1 trial • Oncology • Solid Tumor